Characteristics of Alprazolam-Related Deaths Compiled by a Centralized State Medical Examiner

American Journal on Addictions

Volumn 21, Issue , 2012, Pages S27-S34

  Shah, Neel A ^a   Abate, Marie A ^a   Smith, Michael J ^b   Kaplan, James A ^c   Kraner, James C ^c   Clay, David J ^c  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

^c Office of Chief Medical Examiner   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPRAZOLAM; AMITRIPTYLINE; CITALOPRAM; COCAINE; DEXTROPROPOXYPHENE; DIAZEPAM; DIPHENHYDRAMINE; FENTANYL; HYDROCODONE; METHADONE; MORPHINE; OXYCODONE; HYPNOTIC SEDATIVE AGENT; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CORONER; DRUG INTOXICATION; FORENSIC TOXICOLOGY; HUMAN; MALE; MORTALITY; OBESITY; PRESCRIPTION; RURAL AREA; SUBSTANCE ABUSE; UNITED STATES; ADDICTION; CAUSE OF DEATH; COMORBIDITY; DRUG OVERDOSE; FEMALE; MIDDLE AGED;

ADULT; ALPRAZOLAM; ANALGESICS, OPIOID; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; DRUG OVERDOSE; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; OBESITY; SUBSTANCE-RELATED DISORDERS; WEST VIRGINIA;

EID: 84885937566     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2012.00298.x     Document Type: Article

References (25)

1. Woods JH, Katz JL, Winger G. Benzodiazepines: Use, abuse, and consequences. Pharmacol Rev. 1992; 44: 151-347.
2. Hollister LE, Muller-Oerlinghausen B, Rickels K, et al. Clinical uses of benzodiazepines. J Clin Psychopharmacol. 1993; 13(6 Suppl 1): 1S-169S.
3. Hermos JA,YoungMM,Lawler EV, et al. Characterizations of longterm anxiolytic benzodiazepine prescriptions in veteran patients. J Clin Psychopharmacol. 2005; 25: 600-604.
4. Forrester MB. Alprazolam abuse in Texas, 1998-2004. J Toxicol Environ Health A. 2006; 69: 237-243.
5. Soumerai SB, Simoni-Wastila L, Singer C, et al. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr Serv. 2003; 54: 1006-1011.
6. Risse SC, Whitters A, Burke J, et al. Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. J Clin Psychiatry. 1990; 51: 206-209.
7. Weimer BJ, Peters D, Sannerud C, et al. The National Forensic Laboratory Information System: 2006 Annual Report. Available at: http: //www. deadiversion. usdoj. gov/nflis/2006 annual rpt. pdf. Accessed March 19, 2010.
8. Isbister GK, O'Regan L, Sibbritt D, et al. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol. 2004; 58: 88-95.
9. Kurtz SP, Inciardi JA, Surratt HL, et al. Prescription drug abuse among ecstasy users in Miami. J Addict Dis. 2005; 24: 1-16.
10. Wolf BC, Lavezzi WA, Sullivan LM, et al. One hundred seventy two deaths involving the use of oxycodone in Palm Beach County. J Forensic Sci. 2005; 50: 192-195.
11. Wolf BC, Lavezzi WA, Sullivan LM, et al. Alprazolam-related deaths in Palm Beach County. Am J Forensic Med Pathol. 2005; 26: 24-27.
12. Jenkins AJ, Levine B, Locke JL, et al. A fatality due to alprazolam intoxication. J Anal Toxicol. 1997; 21: 218-220.
13. Michaud K, Augsburger M, Romain N, et al. Fatal overdose of tramadol and alprazolam. Forensic Sci Int. 1999; 105: 185-189.
14. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008; 300: 2613-2620.
15. Centers for Disease Control and Prevention (CDC). Unintentional and undetermined poisoning deaths-11 states, 1990-2001. Morb Mortal Wkly Rep. 2004; 53: 233-238.
16. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf . 2006; 15: 618-627.
17. Coben JH, Davis SM, Furbee PM, et al. Hospitalizations for poisoning by prescription opioids, sedatives, and tranquilizers. Am J Prev Med. 2010; 38: 517-524.
18. Drug Abuse Warning Network. Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Available at: https: //dawninfo. samhsa. gov/data/report. asp?f=Nation/AllMA/ Nation 2009 AllMA ED Visits by Drug. Accessed January 11, 2011.
19. Maxwell JC, McCance-Katz EF. Indicators of buprenorphine and methadone use and abuse: What do we know? Am J Addict. 2010; 19: 73-88.
20. GreenblattDJ,Wright CE. Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet. 1993; 24: 453-471.
21. Winek CL, Wahba WW, Winek CL, Jr, et al. Drug and chemical blood-level data 2001. Forensic Sci Int. 2001; 122: 107-123.
22. Regenthal R, KruegerM, Koeppel C, et al. Drug levels: Therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput. 1999; 15: 529-544.
23. Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003; 58: 447-474.
24. Wysowski DK. Surveillance of prescription drug-related mortality using death certificate data. Drug Saf . 2007; 30: 533-540.
25. Paulozzi LJ, Weisler RH, Patkar AA. A national epidemic of unintentional prescription opioid overdose deaths: How physicians can help control it. J Clin Psychiatry. 2011; 72: 589-592.